Related Experiment Video
Updated: Jun 25, 2026

08:24
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
Published on: November 25, 2022
Driving amyloid toxicity in a yeast model by structural changes: a molecular approach
Karine Berthelot1, Françoise Immel, Julie Géan
1Institut de Biochimie et Génétique Cellulaires, IBGC CNRS UMR 5095, Université Bordeaux 2 Victor Segalen, 1 rue Camille Saint Saëns, 33077 Bordeaux cedex, France.
Summary
Researchers compared a toxic amyloid mutant (M8) to wild-type (WT) Het-s protein. The toxic M8 mutant formed unusual short amyloid fibers with distinct structural properties, suggesting a new aggregation pathway linked to cellular toxicity.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- Amyloid aggregation is implicated in various diseases.
- In vitro studies show specific intermediates contribute to cellular toxicity.
- A toxic yeast mutant (M8) of the harmless Het-s(218-289) protein was previously generated.
Purpose of the Study:
- To compare the aggregation characteristics of wild-type (WT) and toxic mutant (M8) Het-s proteins at a molecular level.
- To elucidate the structural differences contributing to the toxicity of amyloid aggregates.
Main Methods:
- Transmission electron microscopy (TEM) to visualize fiber morphology.
- X-ray diffraction to analyze aggregate structure.
- Fourier transform infrared spectroscopy (FTIR) to determine secondary structure organization (beta-sheet arrangement).
Main Results:
- Both WT and M8 proteins formed fibrillar amyloid aggregates.
- M8 formed unusually short (80 nm), unbranched fibers.
- M8 aggregates exhibited different dye-binding properties and X-ray diffraction patterns compared to WT.
- FTIR revealed M8 beta-sheets had mixed parallel and antiparallel organization, while WT was predominantly parallel.
Conclusions:
- The toxic amyloid mutant M8 displays distinct aggregation characteristics compared to WT Het-s.
- The unique structural features of M8 amyloid fibers, including mixed beta-sheet organization, may be linked to its cellular toxicity.
- This suggests a novel amyloid aggregation pathway contributing to disease pathogenesis.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

